Advertisement
Screener

NewAmsterdam Pharma Company N.V. (NAMS) Graph

2.6 / 5 stars · 15/29 Roast Me

Add as a preferred source on Google

NAMS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $3.70M; Research and development $41.67M; Selling, general and administrative $26.89M; Operating expenses $68.56M.
  • 2026-03-31: Revenue $3.04M; Research and development $38.01M; Selling, general and administrative $23.45M; Operating expenses $61.46M.
  • 2025-12-31: Revenue $32.00K*; Research and development $38.59M*; Selling, general and administrative $27.42M*; Operating expenses $66.01M*.
  • 2025-09-30: Revenue $348.00K; Research and development $30.97M; Selling, general and administrative $24.52M; Operating expenses $55.49M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

NAMS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$3.70MOperating expenses$68.56MOperating income-$64.86MResearch & development$41.67MSelling, general& administrative$26.89MPre-tax income-$64.14MNet income-$64.14M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$3.70M$41.67M$26.89M$68.56M(m)-$64.14M
2026-03-31$3.04M$38.01M$23.45M$61.46M(m)-$48.44M
2025-12-31$32.00K*$38.59M*$27.42M*$66.01M*(m)(m)
2025-09-30$348.00K$30.97M$24.52M$55.49M(m)-$72.00M
2025-06-30$19.14M$27.52M$27.26M$54.78M(m)-$17.36M
2025-03-31$2.98M$44.75M$27.15M$71.90M(m)-$39.53M
2024-09-30$29.11M$35.70M$18.41M$54.11M-$1.00K-$16.65M
2024-06-30$2.28M$38.38M$16.48M$54.85M(m)-$39.01M
2024-03-31$1.40M$42.43M$14.45M$56.88M(m)-$93.77M
2023-09-30$2.94M$43.37M$9.13M$52.50M(m)-$47.13M
2023-06-30$1.72M$34.34M$9.86M$44.20M(m)-$38.29M
2023-03-31$8.63M$40.42M$8.06M$48.48M(m)-$42.02M

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$6.74M$79.68M$50.34M$130.03M-$112.58M
2025-06-30$22.12M$72.27M$54.42M$126.68M-$56.89M
2024-06-30$3.68M$80.81M$30.93M$111.74M-$132.77M
2023-06-30$10.35M$74.76M$17.92M$92.68M-$80.31M

Revenue and expense 9 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$22.47M$103.24M$78.94M$182.17M(m)-$128.90M
2024-09-30$32.79M$116.51M$49.34M$165.85M-$1.00K-$149.42M
2023-09-30$13.29M$118.13M$27.05M$145.18M(m)-$127.44M

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$22.50M$141.83M$106.35M$248.19M(m)-$203.00M
2024-12-31$45.56M$151.41M$70.45M$221.85M-$1.00K-$242.00M
2023-12-31$14.09M$159.42M$37.63M$197.06M$27.00K-$177.00M
2022-12-31$102.69M$86.74M$19.51M$106.25M(m)-$22.63M
2021-12-31(m)$28.97M$6.00M$34.98M(m)-$41.78M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Advertisement